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S244 Poster Session IWe previously performed a retrospective study demonstrating
that a consistent lay care partner (CP) during the inpatient hospital
stay was associated with improved survival in allogeneic BMT. We
recently completed a follow up, prospective study which confirmed
that a CP was associated with improved survival. We additionally
captured data concerning coping techniques for the transplanted pa-
tients and their CPs. This analysis focuses on the optimal duration
and frequency of CP, as well as an analysis of coping skills and
outcomes.
For the purposes of this study, a lay care-partner (CP) was defined
as one person with the patient five or more days a week, beginning
upon admission. Allogeneic patients transplanted from 10/03 to
10/08 were asked to enroll in this study, and 164 of 213 enrolled.
Patients and CPs completed a Brief COPE (coping inventory) at
baseline, post-discharge, and 100 days post transplant.
88 patients (54%) had a CP. 68% of CPs were female, 60% were
a spouse, 30% were a parent, and 88% lived with the patient prior to
admission. CPs were with patients a median of 6.5 hours per day in-
hospital and median frequency of days with patient was 86% of inpa-
tient hospital days. Significantly better survival rates associated with
CP duration of. 3 hours per day in-hospital (P5 0.004) andCP fre-
quency of visits. 75% of inpatient days (P5 0.004). At 4 years post-
transplant, 42% of those with CPs are still alive versus 26% of
patients without CPs.
The data reveals that at baseline, there were statistically significant
correlations in coping between patient and CP on self-distraction (P
5 \ 0.001), use of emotional support (P 5 0.027), humor (P 5
0.017), religion (P 5\ 0.001), and self-blame (P 5 0.028). All of
the correlations were positive, indicating that as patient scores in-
crease CP scores also increased. Significant and positive correlations
were also found for venting (P 5 0.047) and acceptance (P 5 0.015)
at post-discharge, and for use of emotional support (P 5 0.029) and
use of instrumental support (P 5 0.042) at day 100 post-transplant.
Educating patients and CPs about the impact on survival of
optimal levels of CP support is important. Yet, BMT teammembers
are faced with counseling family members about the importance of
having an inpatient lay CP without provoking anxiety about respon-
sibility for patient survival. Providing a support program for CPs is
essential considering their vital contribution to patient outcomes
and their positive impact on patient coping.245
THE EXPERIENCE OF CAREGIVERS OF HEMATOLOGICAL CANCER
PATIENTS UNDERGOING A HEMATOPOIETIC STEM CELL TRANSPLANT:
A COMPREHENSIVE LITERATURE REVIEW
Beattie, S., Lebel, S. University of Ottawa, Ottawa, ON, Canada
Purpose: Although hematopoietic stem cell transplant (HSCT) has
become awell-established treatment formalignancies, it is a demand-
ing procedure with associated physical and psychological sequelae
that can affect patients and their family members. Caregivers to
HSCT patients not only have to cope with the life-threatening na-
ture of the disease and treatment, but they also have care-giving re-
sponsibilities. This study reviews the literature on the psychosocial
impact of being a caregiver to a HSCT patient.
Methods: A critical review of the literature published before June
2010 was conducted. Databases searched included CINAHL, Med-
line, PsycInfo, and Academic Search Complete, as well as a compre-
hensive reference review. Studies that pertained to caregivers of
children (under the age of 18) undergoing a HSCT or caregivers
to patients with non-hematological malignancies were excluded.
Fourteen original quantitative research articles and three qualitative
research articles were reviewed and analyzed.
Results: Caregiver distress is highest pre-transplant and decreases
over time, and caregivers display distress levels comparable to or
higher than patients’ reported distress levels. Predictors of caregiver
distress include gender, higher levels of subjective burden, and pa-
tient symptom distress. Caregivers reported uncertainty, fear of the
future, juggling patients’ needs with their own, and difficulties adapt-
ing to role changes; however, they also reported positive aspects to
care giving.
Conclusion:There are many limitations to the current research, in-
cluding small heterogeneous samples of caregivers and a lack of dy-
adic studies focusing on the reciprocal relationships between thepsychosocial functioning of the patient and caregiver. Future re-
search should be targeted towards unmet needs, identifying sub-
groups of caregivers who are more vulnerable to increased
distressed and poor psychosocial adaptation, and how the patient
and the caregiver reciprocally impact each other’s psychosocial ad-
justments over the transplant trajectory. Also, future research should
have direct clinical applications, by focusing on psychosocial inter-
ventions for HSCT caregivers, either with the patient or in a support
group format.246
ONCOFERTILITY: PRESERVING THE FUTURE FOR CHILDREN, ADOLES-
CENTS AND YOUNG ADULTS THROUGH PATIENT EDUCATION AND CLIN-
ICAL PRACTICE
Rosipal, N.C., Herrera Bell, D., Franklin, A.R.K. MD Anderson Cancer
Center, Children’s Cancer Hospital, Houston, TX
As advances in cancer treatment have led to improved survival
rates, the need to focus on quality of life has become evident. Every
year approximately 70,000 adolescents and young adults (AYA) aged
15-39 years and 10,000 children (\15 years) are diagnosed with can-
cer. The potential loss of fertility secondary to treatment has been
identified as a significant cause of distress in survivors. The risk of in-
fertility depends on multiple factors including the patient’s age, gen-
der, cancer diagnosis and treatment. For children and AYAs
undergoing stem cell transplantation, this risk is over 80%. Women
also have an increased risk of premature ovarian failure, which can
threaten bone and heart health. Survivorship literature reports
most patients do not recall a discussion about the potential loss of
fertility and available preservation options with their oncology
team. This information gap has led to the development of guidelines
by the American Society of Clinical Oncology (ASCO) advising that
the risk of infertility be explicitly discussed. AtMDAndersonCancer
Center, we have responded to this unmet need by implementing an
oncofertility consultation service. A pediatric oncologist and 2 nurse
practitioners with an interest in fertility see patients three half days
a week in the pediatric clinic. Our goals are to:
1) educate the patient about their unique infertility risk based on
Tanner staging and medical history
2) educate the patient about possible fertility preservation options,
3) educate female patients about the possibility of premature ovarian
failure and its implications regarding fertility, bone density and
heart disease,
4) refer patients to appropriate specialists for more specific counsel-
ing and or preservation procedures,
5) research the decision-making process involved in pursuit of fertil-
ity preservation
6) educate the institution and our colleagues on this topic
7) evaluate the impact of the service
Childhood and AYA cancer patients and their families must be
given opportunity to have an open discussion regarding the impact
cancer and its treatment may have on their future fertility as well
as current potential preservation options. We have developed
a consult service as an avenue to facilitate this information sharing
in a focused and open manner.LEUKEMIA
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PHILADELPHIA CHROMOSOME IS NOT AN ADVERSE PROGNOSTIC
FACTOR IN ACUTE LYMPHOBLASTIC LEUKEMIA AFTER MYELOABLATIVE
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Postow,M.1, Kim, H.T.2, Sun, L.2, Koreth, J.3, Armand, P.3, Cutler, C.3,
Alyea, E.P.3, Antin, J.H.3, Soiffer, R.J.3, Ho, V.T.3 1Memorial Sloan
Kettering Cancer Center, New York, NY; 2Dana-Farber Cancer Institute,
Boston, MA; 3Dana-Farber Cancer Institute, Boston, MA
Philadelphia chromosome positive (Ph1) acute lymphoblastic
leukemia (ALL) is associated with poor prognosis with conventional
chemotherapy. Whether Ph1 predicts poor prognosis after allo-
SCT is not well defined. We reviewed 157 adult patients with
ALL (Ph152; Ph- 5 105) who underwent myeloablative allo-SCT
Poster Session I S245at our institution from 1998 to 2009. Most received Cy/TBI (97%)
based regimens. Ph1 group was older, median age 42 yrs. vs. 38
yrs, p 5 0.02. The 2 groups were balanced in distribution of condi-
tioning regimen, donor and stem cell source, HLAmatch, CMV sta-
tus, and WBC at diagnosis. 73% of the Ph1 were transplanted in
CR1, vs. 37% of the Ph- (p 5 0.0001). There was no difference in
time to neutrophil/platelet engraftment, grade II-IV acute GVHD
(28% vs. 31%), and chronic GVHD (53% vs. 51%) in the Ph1 vs.
Ph- groups, respectively. 3-year cumulative incidence of non-relapse
mortality and relapse (as competing risks) were 24% vs. 29% (p 5
0.66) and 34% vs. 41% (p5 0.56), for Ph1 vs. Ph- patients, respec-
tively. With median follow-up of 36 and 48 months after transplant,
there was no difference in 3-year progression free survival (PFS) and
3-year overall survival (OS) from time of transplant for Ph1 and Ph-
patients (PFS: 40% vs. 32%, p5 0.53; OS: 48% vs. 34%, p5 0.36).
To adjust for more patients in the Ph1 group being transplanted in
CR1, we also assessed survival from time of ALL diagnosis. 3-year
PFS and OS from time of ALL diagnosis for the Ph1 and Ph- pa-
tients were similar (PFS 48% vs. 48%, p 5 0.67; OS 50% vs. 49%,
p 5 0.93). In subset analyses restricted to patients transplanted in
CR1, 3-year PFS and OS were also similar in Ph1 vs. Ph- patients
(PFS: 51% vs. 35% p 5 0.59; OS: 53% vs. 40% p 5 0.58, respec-
tively). In multivariable models, more recent year of transplant was
associated with an improvement in PFS (HR 0.88, 95% CI 0.77-
0.99, p 5 0.04), and a trend toward better OS (HR 0.88, 95% CI
0.77-1.01, p 5 0.06) in the Ph1, but not Ph- cohort. There was
a trend towards improved 3-year OS for all patients transplanted af-
ter 2001, the year of imatinib approval, (OS5 42%) vs. before 2001
(OS 5 26%), P 5 0.15. In competing risks regression modeling,
WBC at diagnosis . 100K and bone marrow graft (vs. PBSC)
were significant factors associated with increased relapse in Ph1 pa-
tients. Our data suggest that followingmyeloablative allo-SCT, Ph1
ALL patients have similar outcomes compared to patients with Ph-
ALL, even when adjusted for disease stage at time of transplant.248
REDUCED TOXICITY MYELOABLATIVE CONDITIONING REGIMENS (RTC)
COMPARED WITH STANDARD MYELOABLATIVE CONDITIONING PRIOR
TO ALLOGENEIC STEM CELL TRANSPLANTATION IN AML AND MDS;
RTC HAS MORE FAVORABLE TOXICITY PROFILE BUT MORE LIMITED
LEUKEMIA CONTROL IN ADVANCED DISEASE
Shimoni, A., Rand, A., Shem-Tov, N., Volchek, Y., Yerushalmi, R.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic stem cell transplantation (SCT) is a curative therapy
for patients (pts) with AML and MDS. Standard myeloablative con-
ditioning (MAC) is associated with high rates of non-relapse mortal-
ity (NRM). Reduced-intensity conditioning reduces NRM but
relapse rates are higher. Reducing toxicity without compromising
SCT efficacy could be of a significant benefit. Novel reduced toxicity
myeloablative regimens (RTC) such as fludarabine with myeloabla-
tive doses of busulfan or treosulfan were designed to achieve this
goal, however their relative merits in different settings are not well
established. We analyzed SCT outcomes in a group of 252 pts
[AML-199 (66 secondary), MDS-53], median age 50 (17-76), given
SCT from related (n 5 144) or unrelated donors (n 5 108). Disease
status at SCT was defined as early (n5 81), intermediate (n5 54) or
advanced (n 5 117) by CIBMTR criteria. Eligible pts were given
MAC (BuCy, n5 90). Pts considered at high risk for NRM, but still
eligible for myeloablation were given RTC (n5 162). This group in-
cluded older pts (median age 55 Vs 39 years), more pts with comor-
bidity index . 2 (19% Vs 5%) and more unrelated donors. With
median follow-up of 36 months (1-129), 119 are alive, 52 had
NRM and 81 died of relapse. The 5-year overall survival (OS) is
41% (95CI, 34-48). It was 43% and 40% after MAC and RTC, re-
spectively (p 5 NS). NRM was 21% in both and relapse was 36%
and 39%, respectively (p5NS). Multivariable analysis (MVA) iden-
tified advanced disease as the major adverse factor for OS (HR 2.3, p
\ 0.001). Age . 50 and MAC were risk factors for NRM and ad-
vanced disease for relapse. The conditioning regimen had prognostic
significance in certain settings. Pts with MDS/2AML had better OS
after RTC than MAC; 49% and 37%, respectively (p5 0.07). MAC
(HR 1.9, P 5 0.03) and comorbidity index (HR 1.6, p 5 0.05) were
adverse prognostic factors. These pts were particularly more suscep-
tible to NRM with MAC. Pts with early AML had a trend for betterOSwithRTC; 75%and 47%, respectively (p5NS).MAChad a sur-
vival advantage in pts with intermediate-advanced disease, 45% and
22%, respectively (p5 0.06). This was due to higher relapse rate af-
ter RTC, 58% and 33%, respectively (p5 0.02). In conclusion, RTC
allows SCT in pts at higher risk for NRM with outcomes that are
similar to MAC in eligible pts. RTC may have an advantage in
MDS/2AML and possibly in early AML due to reduction of
NRM. However, MAC has an advantage in more advanced AML
due to better leukemia control.249
MULTI-DIMENSIONAL RESISTANCE PHENOTYPE ALLOWS QUIESCENT
LEUKEMIC STEM CELLS RESIDING AFTER TYROSINE KINASE INHIBITOR
TREATMENT TO ESCAPE FROM IMMUNOLOGICAL INTERVENTIONSWITH
ALLOREACTIVE T CELLS AND NK CELLS
Jedema, I., vanDreunen, L., Hagedoorn, R.S., Falkenburg, J.H.F. Leiden
University Medical Center, Leiden, Netherlands
Chronic myeloid leukemia (CML) is well responsive to various
therapeutic strategies, including tyrosine kinase inhibitors (TKI)
and allogeneic stem cell transplantation combined with donor lym-
phocyte infusion (DLI). Although initial complete responses are fre-
quently achieved, recurrenceof the disease is a commonphenomenon
occurring sometimes years after the therapeutic intervention(s). This
suggests that an initially undetectable subpopulation of leukemic pre-
cursor cells is capable of escaping therapy. In this study, we investi-
gated in detail the phenotype and apoptosis gene expression
fingerprint of this subpopulation of CML precursor cells residing af-
ter TKI treatment and immunological interventions with high affin-
ity cytotoxic donor T cells or NK cells. CD341 positive CML cells
were isolated from bone marrow and the number, phenotype, and
proliferative status of the CML cells residing after therapeutic inter-
vention(s) were measured by quantitative flowcytometry. Although
the majority of CML precursor cells and their malignant progeny
were efficiently targeted, a small subpopulation of non-dividing
CD34 bright cells, comprising on average 0.05-0.2% of the initial
CD341 population, showed cross-resistance to the different strate-
gies. In the absence of therapeutic pressure these cells were capable
of producingmalignant progeny. Phenotype analysis showed inferior
expression of HLA-class I and several adhesion molecules crucial for
the formationof a high avidity interactionwith immune effector cells,
includingCD54, CD58 andCD49d.Next, we compared the apopto-
sis gene expression fingerprint of this resistant subpopulation with
the profile of total CD341CMLprecursor cells and their proliferat-
ing malignant offspring using a quantitative array PCR containing
probes for 86 apoptosis-related genes (SABiosciences). This genetic
profiling revealed significant downregulation (4-182 fold) of crucial
players of the different main apoptosis pathways, including caspase-
3 and -8, Fas, TNFR, and different association molecules like
FADD, TRADD, and TRAFs, and a 4.8-6.2 fold upregulation of
the most important inhibitor of the death receptor pathway c-FLIP
(CFLAR). Interestingly, we observed a 55 fold downregulation of
the TKI-targeted fusion gene partner Abl1. These data show that
a subpopulation of CML precursor cells with potential self-renewal
capacity harbors a multi-dimensional resistance phenotype allowing
them to escape from different therapeutic strategies.250
SUCCESSFUL MANAGEMENT OF REFRACTORY/RECURRENT ACUTE MYE-
LOID LEUKEMIA BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION AND PROPHYLACTIC IMMUNOTHERAPY
Wang, J.-B., Wu, T., Da, W.-M., Sun, Y., Zhao, Y.-L., Cao, X.-Y.,
Yin, Y.-M., Lu, Y., Zhou, J.-R., Gao, Y.-Q., Zhang, J.-P., Luo, R.-
M., Zhang, Y.-C., Ji, S.-Q., Lu, D.-P., Tong, C.-R. Beijing Daopei
Hospital, Beijing, China
Our previous study has shown that donor’s dendritic cell-primed
cytokine-induced killer cell (DC-CIK) is a safe and effective thera-
peutic mean in management of early leukemia recurrence after allo-
geneic hematopoietic stem cell transplantation (HSCT) (JB Wang,
et al.ASH 2008). In present clinical study, the efficacy of refrac-
tory/recurrent acute myeloid leukemia (AML) salvaged by HSCT
and prophylactic immunotherapy is evaluated. From September
